GlassScriptPhysician profile
Susan B Gain
NPI 1477552347
$3,255.31
in general payments reported to CMS, 2019-2025
28 companies · $869 in 2025
The $869 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $533 · 2023: $724 · 2024: $900 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,492.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $938.41 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $490.24 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $371.95 | 2022-2025 | |
| Genentech USA, INC. | $148.16 | 2021-2023 | Evrysdi |
| Abbvie INC. | $128.76 | 2023-2025 | |
| Eisai INC. | $121.18 | 2021-2023 | |
| Biogen, INC. | $110.59 | 2024-2025 | Skyclarys, Spinraza |
| Catalyst Pharmaceuticals, INC. | $94.16 | 2023-2024 | Fycompa |
| Sumitomo Pharma America, INC. | $91.52 | 2023-2024 | Aptiom |
| Sunovion Pharmaceuticals INC. | $81.97 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $70.37 | 2024-2025 | Motpoly Xr |
| Sk Life Science, INC. | $68.28 | 2023-2025 | |
| Immedica Pharma US, INC. | $64.82 | 2023-2024 | |
| Upsher-Smith Laboratories LLC | $54.07 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $48.31 | 2025 | Daybue |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $45.22 | 2024-2025 | Dysport |
| Ns Pharma, INC. | $43.37 | 2021-2023 | Viltepso |
| Supernus Pharmaceuticals, INC. | $42.27 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $33.83 | 2024-2025 | Zonisade |
| Sarepta Therapeutics, INC. | $30.71 | 2023 | Elevidys |
| Piramal Critical Care | $25.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.82 | 2024 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $24.05 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.68 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.35 | 2025 | Ajovy |
| Genzyme Corporation | $18.50 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.94 | 2023 | Lyvispah |
| Medtronic, INC. | $17.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Gain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.